Sentnyl Therapeutics, Inc. Re-Launches Abstral® in the United States
Sentynl Therapeutics, Inc. (“Sentynl”) announced that its commercial organization relaunched Abstral® in the United States. Sentynl acquired the rights to market Abstral® from Galena Biopharma in November 2015. Abstral® is indicated for the management of breakthrough pain... - May 01, 2016
Sentynl Therapeutics, Inc. Acquires Abstral®
Sentynl Therapeutics, Inc. (“Sentynl”) announced that it acquired the rights to market Abstral® in the U.S. from Galena Biopharma. Abstral® is indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are... - May 01, 2016
Sentynl Therapeutics, Inc. Launches Sentynl Patient Services
Sentynl Therapeutics, Inc. (“Sentynl”) announced that it launched Sentynl Patient Services to enhance patient access to its products. Sentynl Patient Services provides support to patients who want assistance with investigating their benefits, affording their medications and locating... - May 01, 2016
Sentynl Therapeutics, Inc. Welcomes Darren Pincus as Vice President of Business Development
Sentynl Therapeutics, Inc. (“Sentynl”) announced that Darren Pincus joined Sentynl as its Vice President and head of Business Development. Mr. Pincus is a highly experienced business development professional with a strong track record of successfully completed transactions. Prior to... - May 01, 2016
Sentynl Therapeutics, Inc. Launches Its Commercial Organization
Sentynl Therapeutics, Inc. (“Sentynl”) announced that it launched its commercial organization including a full-time, professional sales force of key account specialists. About Sentynl Therapeutics. Sentynl provides healthcare professionals with treatment solutions that enable them to... - April 30, 2016
Sentynl Therapeutics, Inc. Welcomes Michael Hercz as Its Senior Vice President and General Counsel
Sentynl Therapeutics, Inc. (“Sentynl”) announced that Michael Hercz joined Sentynl as its Senior Vice President, General Counsel and Chief Compliance Officer. Mr. Hercz brings more than 18 years of legal, compliance and risk management experience to Sentynl. Prior to Sentynl, Mr. Hercz... - April 30, 2016